Zetomipzomib – PALIZADE study
Zetomipzomib is a selective immunoproteasome inhibitor that specifically targets the inflammatory cells. The drug was shown to reduce the production of proinflammatory cytokines from mononuclear cells, block T-cell production of IFN-γ, tumor necrosis factor-α, and granulocyte-macrophage colony-stimulating factor, and the differentiation of B cells to plasmablasts.
Enroll in this clinical study
How is Zetomipzomib being studied in Lupus nephritis?
The efficacy and safety of zetomipzomib in achieving renal response in patients with active lupus nephritis is being studied in the PALIZADE study. This is a phase 2b, randomized, controlled double-blind, multicenter study comparing Zetomipzomib (KZR-616) 30 mg or 60 mg with placebo in patients with active lupus nephritis. The primary endpoint is to evaluate efficacy (the proportion of patients achieving complete renal response) and safety (incidence and severity of adverse events).
Eligibility Criteria
Body mass index of ≥18 kg/m^2
eGFR ≥30 mL/min/1.73 m^2
Unequivocally positive ANA test result and/or a positive anti-dsDNA serum antibody test
Diagnosis of LN according to 2003 or 2018 ISN/RPS criteria and confirmed by renal biopsy performed within 12 months prior to Screening.
UPCR ≥1.0 (Class III/IV +/-V) or UPCR ≥2.0 (Class V)
Adequate hematologic, hepatic, and renal function
Link to study website: